Financials data is unavailable for this security.
View more
Year on year Oxford Biomedica PLC had net income fall from a gain of 19.01m to a loss of 39.16m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 10.61% to 20.16%.
| Gross margin | 46.20% |
|---|---|
| Net profit margin | -58.97% |
| Operating margin | -51.93% |
| Return on assets | -16.18% |
|---|---|
| Return on equity | -31.27% |
| Return on investment | -21.95% |
More ▼
Cash flow in GBPView more
In 2022, Oxford Biomedica PLC increased its cash reserves by 29.69%, or 32.34m. Cash Flow from Financing totalled 98.62m or 70.45% of revenues. In addition the company used 12.62m for operations while cash used for investing totalled 56.46m.
| Cash flow per share | -0.4373 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1.78 |
|---|---|
| Tangible book value per share | 0.769 |
More ▼
Balance sheet in GBPView more
| Current ratio | 3.32 |
|---|---|
| Quick ratio | 3.07 |
| Total debt/total equity | 0.6574 |
|---|---|
| Total debt/total capital | 0.3635 |
More ▼
Growth rates in GBP
Year on year, growth in earnings per share excluding extraordinary items dropped -286.00%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -143.79 |
